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Abstract
Mitochondrial disorders are multisystem conditions that can potentially affect gait in many ways. The aim of this study was to
select the optimal protocol to quantify the spatiotemporal parameters of gait in ambulatory children with mitochondrial disorders
based on feasibility, test-retest reliability, and the difference between patients and controls. Gait at self-selected pace was
quantified in ambulatory children with a genetically confirmed primary mitochondrial disease using the GAITRite electronic
walkway. Three protocols were tested: pre-exercise, post-exercise (after a 3-min walking test), and recovery. In 14 ambulatory
patients, we showed good to perfect reliability for velocity, cadence, step length, step time, step time variability, and step width in
the recovery condition. The difference between patients and 70 individually age- and gender matched healthy controls only
became apparent in the post-exercise protocol. In conclusion, measuring spatiotemporal parameters of gait using the GAITRite in
ambulatory children with mitochondrial disease is feasible and reliable for most of the parameters measured. When using gait
analysis in future studies in children with mitochondrial disease, we advise i) to use an exercise test prior to the gait analysis, ii) to
let children practice the test before the actual data collection, and iii) not to use symmetry parameters.
Introduction
Mitochondrial disorders are multisystem conditions that can
potentially affect gait in many ways. Since mitochondria are
present in almost all cells of the human body, signs and symp-
toms of all organs may arise, though they are generally most
pronounced in the organs with the highest energy consumption
(Koopman et al 2016). Mitochondrial disorders are caused by
mutations in one of the 1150 nuclear genes encoding proteins
involved in oxidative phosphorylation or in mutations in the
small circular mitochondrial DNA (Pagliarini et al 2008; Calvo
et al 2016). Mitochondrial DNA (mtDNA) mutations are co-
existent with healthy mtDNA in variable proportions per cell,
called heteroplasmy. With an estimated total prevalence of
roughly 1/5000, mitochondrial disease is one of the most com-
mon inherited neuromuscular conditions of metabolism
(Chinnery and Turnbull 2001).
Currently, there is no definite clinically beneficial treatment
for most mitochondrial patients (Gorman et al 2015). Several
recent collaborative papers of mitochondrial experts around
the globe suggest that validated, clinically meaningful out-
come measures should be used to detect clinically relevant
effects of treatments (Pfeffer et al 2012; Pfeffer et al 2013).
Since many mitochondrial disease patients experience diffi-
culties in ambulation (de Laat et al 2012), we and others pre-
viously studied gait analysis with the GAITRite electronic
walkway in adults with a mitochondrial disease (Galna et al
2014; Ramakers et al 2017). Both studies showed that the
GAITRite was able to quantify subtle changes in the balance
and strength of these adults with mitochondrial disease and
that reliability of the gait analysis was good to perfect.
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Since 86% of children with mitochondrial disease also ex-
perience severe difficulties in walking (Koene et al 2013), we
hypothesized that gait analysis is also a widely applicable and
reliable outcome measure for children with mitochondrial
disease.
The aim of this study was to select the optimal protocol
(with good feasibility and the highest test-retest reliability) to
quantify the spatiotemporal parameters of gait in ambulatory
children with mitochondrial disorders, comparing three differ-
ent protocols (pre- and post exercise and recovery). Secondly,
the gait pattern of each of the mitochondrial patients was in-
dividually compared to five age- and gender matched healthy
controls to gain more insight in which walking parameters
were altered in children with mitochondrial disease. Finally,
validity was assessed by correlating the gait parameters with
the 3-min walking test (3MWT) distance, a measure for func-
tional walking capacity.
Methods
Study subjects
Children with a genetically confirmed primary mitochondrial
disease who were able to walk 30 m five times according to
parents were included in this study. Per patient, five individu-
ally age- (±0 years) and gender matched healthy controls were
recruited via colleagues within the hospital, sports clubs, and
social media. Exclusion criteria for this study were: any other
disease causing abnormal gait pattern (e.g., orthopedic, other
neurological or neuromuscular diseases) and/or severe behav-
ioral problems. The ethics committee of Arnhem-Nijmegen
r eg ion , The Ne the r l ands , app roved th i s s t udy
(NL58062.091.16). Parents and children ≥12 years of age
gave written informed consent before participation.
Measurements
Anthropometric data were collected for each subject before
gait assessment. Leg length was measured as true leg length,
from the Anterior Superior Iliac Spine (ASIS) toward the me-
dial malleolus on both sides. Genetic and clinical data were
collected from the charts.
Gait analysis and data processing
A portable GAITRite electronic walkway system was used to
quantify gait patterns (Platinum model GAITRite, software
version 4.8.5, CIR systems, USA). The system was set up in
a laboratory setting and consisted of a 7 m long walkway with
2 m free walking space at both ends for acceleration (Fig. 1a).
All spatiotemporal gait parameters were captured by the
GAITRite software. Incomplete footfalls and scrubs were
removed. We have focused our gait analysis based on the
model introduced by Lord et al in 2013 (Lord et al 2013).
This model consists of five domains for assessing gait includ-
ing pace (step length and step velocity), rhythm (step time),
variability (step length and step time variability), asymmetry
(step time asymmetry), and postural stability (step width, step
width variability and step length asymmetry) (Lord et al
2013). Mean velocity, step length, step time, and step width
were calculated for each protocol. Variability of step length,
time, and width was calculated as the root of the mean vari-
ance of the left and right foot. Step time- and step length-
asymmetry was defined as the absolute difference between
both feet. Velocity, cadence and average step length were nor-
malized for leg length according to Stansfield et al (Stansfield
et al 2003).
Gait assessment
Participants were instructed to refrain from walking for long
distances at the day of the measurements and to come to the
clinic using the hospital transportation or a wheelchair. All
patients rested for at least ten minutes while the study was
explained and informed consent was given.
Children were instructed to walk across the GAITRite-mat
barefoot at their self-selected pace (Bas if you were in your
house^). All subjects started 1 m before the mat and stopped at
least 1 m after the mat (Fig. 1a) to minimize the effect of
acceleration and deceleration.
We have tested three protocols: normal walking at self-
selected pace before the 3MWT (pre-exercise protocol; test
1 and 2), and after the 3MWT to test the influence of exercise
(post-exercise protocol; test 3 and 4) and a protocol to assess
the recovery after a 10-min break in which the child sat on a
chair (recovery protocol; test 5), see also Fig. 1b. Each of the
five tests consisted of three walks (trials) across the mat with-
out breaks in between. There was a one-minute break between
test 1 and 2 and between 3 and 4 in which the child sat on a
chair. The order and timing of the protocol was fixed to pre-
vent influences of the exercise-induced exhaustion with the
pre-exercise protocol.
Subjects who were not able to understand the instruc-
tions were encouraged by a parent or investigator standing
on the other side of the mat with a motivational toy or
object. If participants were not able to complete three
valid trials within 3 min, the test was noted as Bmissing^.
Cooperation was noted on a self-developed 1–5 scale by
the researcher, where 1 is no cooperation, 2 is cooperation
with distraction and/or lack of understanding of the in-
structions leading to >2 repeats of trials, 3 is limited co-
operation leading to 1–2 repeats of trials, 4 cooperation
with little distraction not obviously affecting the gait, and
5 is complete and direct cooperation.
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3-min walking test
Between test 2 and 3, the 3-min walking distance test (3MWT;
pylons 25 m apart, standardized every-minute encourage-
ments BOne minute, two more minutes to go, you’re doing
well^) was performed to assess their functional ambulation
capacity and to inducemuscular tiredness. The 3MWT instead
of the 6-min walking test was selected because of the higher
feasibility and lower burden to the children. When the child
was not able to comply with the instructions of the 3MWT,
muscular fatigue was induced by playing for 3 min and the
distance of the 3MWTwas not noted.
Validity
The correlation between gait parameters and the 3MWT was
assessed to test the validity of the spatiotemporal parameters.
Statistical analysis
All data are presented as median and range unless otherwise
specified. To test the reliability of the gait parameters mea-
sured with the GAITRite, Intraclass Correlation Coefficients
for agreement (ICCs) were calculated for each study group,
variable and protocol. ICCs above 0.7 were defined as ‘ac-
ceptable’, above 0.8 were defined as ‘good’ and above 0.9
‘perfect’. Furthermore, we tested differences between patients
and their healthy age- and gender matched controls at the pre-
exercise protocol (second test) and the post exercise protocol
(third test) using the paired non-parametrical Friedman test in
non-Gaussian distribution; statistical significance has been de-
fined as p < 0.05 (two-tailed). Correlation analysis was carried
out between the 3MWT and the different gait characteristics
for the pre-exercise protocol (second test) only. Since this is an
explorative study, we did not correct for multiple testing.
Results
Study subjects
Fourteen ambulatory children with genetically-confirmed mi-
tochondrial disease and 70 age- and gender matched controls
were included in this study (Table 1). Because two 10-year-old
boys with mitochondrial disease were included and insufficient
10-year-old controls could be recruited, they were matched to
three or four 10-year-old and two or one 11-year-old boys each.
The physical characteristics of the patients and controls are
present in Table 1 and the disease specific characteristics of
the patients are presented in Table 2. The most common signs
and symptoms of the patients were exercise intolerance (n = 10)
and psychomotor retardation (n = 5). Six out of 14 children
carried the m.3243A >G mutation (heteroplasmy percentages
in urinary epithelial cells 61–96%). Patients had significantly
shorter leg length compared to controls, but height, weight, and
BMI showed no statistically significant differences (Tables 1
Fig. 1 a. Schematic
representation of the GAITRite
walkway setup. Children started
2 m in front of and ended 2 m
behind the actual GAITRite
walkway to ensure they would
have a constant walking speed.
Reproduced with permission of
Biomed Central
b. Gait assessment flowchart. All
subjects completed the same
rotation of trial conditions and
were given the same resting
period. Each condition consisted
of th ree walks ac ross the
GAITRite walkway
J Inherit Metab Dis (2018) 41:731–740 733
and 2). Patients had a significantly lower 3-min walking dis-
tance compared to their healthy peers (215 m versus 235 m,
respectively; p = 0.03).
Feasibility
All participants completed the full protocol. Three patients
showed low cooperation (<4, meaning that the child was eas-
ily distracted or did not understand the instructions leading to
one or more repeats of trials), one patient cooperated, but with
no full understanding of the tasks, and ten patients completed
the protocol fully cooperatively. Of the healthy controls, only
one out of 70 children was not always cooperative, three con-
trols cooperated with no full understanding of the tasks, and
66 controls were fully cooperative. Patients were significantly
less cooperative in almost all protocols (Table 1).
Gait characteristics
Comparisons of the gait characteristics per group for each
protocol are shown in Table 3. Patients and controls showed
no statistically significant differences for the pre-exercise pro-
tocol. In the post-exercise protocol, only step length variabil-
ity and step width variability reached significance (3.8 cm
(patients) versus 3.2 cm (controls); p = 0.02 and 3.5 cm versus
2.7 cm; p = 0.05, respectively). When comparing the spatio-
temporal parameters of pre- and post-exercise gait, patients
have an increased step time asymmetry (5.0 ms (pre-
exercise) versus 13.0 ms (post-exercise); p = 0.008). While
healthy controls increase their step length and decrease step
width (3.1 cm (pre-exercise) versus 3.2 cm (post-exercise);
p = 0.02 versus 9.0 cm (pre-exercise) and 8.5 cm (post-
exercise); p = 0.008, respectively), these parameters did not
reach statistical significance in patients.
Reliability
ICCs of the gait parameters for the different protocols are pre-
sented in Table 4. In patients, good to perfect reliability was
found for velocity, step length, and step width for all protocols
(ICC > 0.8). When only cooperative patients were assessed in
the recovery protocol, six out of ten parameters showed good or
perfect reliability. Although the ICCs in the clinically more
homogeneous control group tended to be lower, especially for
step width, a similar pattern of the reliability of the parameters
in the various protocols was found in the healthy control group.
Validity
In patients, none of the spatiotemporal gait parameters corre-
lated significantly to the 3MWT distance. In healthy controls,
we only found statistically significant correlations between the
3MWT distance and normalized velocity (r = −0.33; p =
0.006), normalized step length (r = 0.43; p < 0.001), and step
width (r = 0.29; p = 0.03) in the pre-exercise protocol.
Discussion
To our knowledge, this is the first study to investigate the fea-
sibility and same day test-retest reliability of gait analysis in
children with genetically-confirmed mitochondrial disease.
This exploratory study in 14 ambulatory patients showed good
feasibility of the GAITRite in quantifying the spatiotemporal
parameters in this population. We found good to perfect
Table 1 Study population
demographics Patients (n = 14) Controls (n = 70) Difference
(p-value)
median range median range
Gender (% female) 43 43
Age (years) 11 (5–16) 11 (5–16) 0.05
Height (cm) 147 (101–168) 154 (109–187) 0.11
Weight (kg) 38.2 (14.9–57.0) 41.2 (17.7–108.5) 0.63
BMI (kg/m2) 17.8 (13.9–21.2) 18 (12.8–33.3) 0.75
Leg length (mean) 75 (46–85) 82 (53–100) 0.02
3-min walking test (distance, m) 215 (131–283) 235 (180–370) 0.03
Cooperation first test (1–5 scale) 5 (2–5) 5 (3–5) 0.03
Cooperation second test (1–5 scale) 5 (3–5) 5 (3–5) 0.05
Cooperation third test (1–5 scale) 5 (3–5) 5 (3–5) 0.04
Cooperation forth test (1–5 scale) 5 (2–5) 5 (3–5) 0.05
Cooperation fifth test (1–5 scale) 5 (2–5) 5 (4–5) <0.001
Cooperation 3MWT (1–5 scale) 5 (2–5) 5 (4–5) 0.06
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reliability for six out of ten gait parameters in the recovery
protocol. Reliability was highest in the recovery protocol, sug-
gesting that practice is required before the first walk is regis-
tered. The difference between patients and healthy controls,
however, only became apparent in the post-exercise protocol.
In this small cohort, none of the spatiotemporal parameters
correlated significantly to the distance walked at the 3MWT.
Gait is an extremely complex process, involving the interac-
tion between the musculoskeletal system and central and
peripheral nervous system. Larger studies in adults with mito-
chondrial disease showed discrete but statistically significant
differences for velocity, step length, step length variability, step
time variability, and step width variability between patients and
controls (Galna et al 2014; Ramakers et al 2017). Despite
matching the patients individually to five age- and gender
matched controls, we could only detect statistically significant
differences between patients and controls in step length and step
width variability after exercise as performed in the 3MWT.
Table 4 Intra class correlations coefficients (ICCs) of the gait parameters for each walking protocol
Pre-exercise protocol (test 1 versus 2)
Patients (n = 14) Controls (n = 70) Cooperative patients (n = 11)
ICC 95%CI ICC 95%CI ICC 95%CI
Velocity (cm/s) 0.900 (0.721–0.967) 0.775 (0.662–0.854) 0.941 (0.807–0.984)
Cadence (step/min) 0.583 (0.132–0.841) 0.908 (0.857–0.942) 0.940 (0.788–0.984)
Step length (cm) 0.971 (0.911–0.990) 0.960 (0.937–0.975) 0.946 (0.813–0.985)
Step length variability (cm) 0.625 (0.145–0.863) 0.336 (0.109–0.529) 0.547 (−0.082–0.857)
Step length asymmetry (cm) 0.162 (−0.432–0.634) 0.426 (0.213–0.600) 0.211 (−0.438–0.712)
Step time (ms) 0.580 (0.127–0.893) 0.934 (0.895–0.958) 0.917 (0.724–0.977)
Step time variability (ms) 0.726 (0.357–0.902) 0.394 (0.177–0.575) 0.739 (0.265–0.923)
Step time asymmetry (ms) 0.543 (0.0.63–0.824) 0.252 (0.018–0.460) 0.471 (−0.084–0.818)
Step width (cm) 0.980 (0.914–0.994) 0.851 (0.771–0.905) 0.969 (0.811–0.993)
Step width variability (cm) 0.618 (0.135–0.860) 0.463 (0.256–0.629) 0.529 (−0.101–0.850)
Post-exercise protocol (test 3 versus 4)
Velocity (cm/s) 0.835 (0.568–0.944) 0.809 (0.710–0.877) 0.984 (0.934–0.996)
Cadence (step/min) 0.209 (−0.327–0.650) 0.935 (0.897–0.959) 0.970 (0.893–0.992)
Step length (cm) 0.972 (0.916–0.991) 0.950 (0.959–0.984) 0.957 (0.855–0.988)
Step length variability (cm) 0.699 (0.277–0.893) 0.223 (−0.14–0.435) 0.698 (0.180–0.910)
Step length asymmetry (cm) 0.747 (0.372–0.912) 0.543 (0.356–0.689) 0.718 (0.233–0.916)
Step time (ms) 0.403 (−0.114–0.756) 0.946 (0.915–0.966) 0.953 (0.839–0.987)
Step time variability (ms) 0.870 (0.645–0.956) 0.500 (0.301–0.658) 0.841 (0.508–0.955)
Step time asymmetry (ms) 0.411 (−0.062–0.753) 0.430 (0.222–0.601) 0.361 (−0.128–0.755)
Step width (cm) 0.974 (0.917–0.992) 0.893 (0.833–0.932) 0.960 (0.863–0.989)
Step width variability (cm) 0.742 (0.315–0.913) 0.451 (0.241–0.620) 0.709 (0.103–0.919)
Recovery protocol (test 2 versus 5)
Velocity (cm/s) 0.977 (0.930–0.992) 0.766 (0.601–0.860) 0.973 (0.904–0.993)
Cadence (step/min) 0.918 (0.701–0.975) 0.880 (0.717–0.940) 0.960 (0.863–0.989)
Step length (cm) 0.945 (0.837–0.982) 0.939 (0.903–0.961) 0.913 (0.719–0.976)
Step length variability (cm) 0.765 (0.416–0.918) 0.277 (0.044–0.481) 0.722 (0.238–0.917)
Step length asymmetry (cm) 0.165 (−0.370–0.624) 0.212 (−0.016–0.422) 0.082 (−0.536–0.633)
Step time (ms) 0.933 (0.735–0.980) 0.888 (0.731–0.944) 0.938 (0.785–0.983)
Step time variability (ms) 0.855 (0.618–0.951) 0.389 (0.173–0.570) 0.889 (0.658–0.968)
Step time asymmetry (ms) 0.380 (−0.125–0.741) 0.519 (0.323–0.671) 0.263 (−0.325–0.722)
Step width (cm) 0.969 (0.904–0.990) 0.782 (0.672–0.859) 0.954 (0.847–0.987)
Step width variability (cm) 0.608 (0.122–0.857) 0.348 (0.125–0.537) 0.626 (0.081–0.884)
ICCs in italic are good (above 0·80) and ICCs in bold are perfect (above 0·90)
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However, the gait parameters deviating most markedly from the
age- and gender matched were found in the most severely af-
fected patients, namely the two patients with Leigh syndrome
and the patient with MELAS syndrome. The two ambulatory
patients with ataxia hadmuchmilder gait abnormalities. In other
pathologies like Parkinson’s disease, it is known that the vari-
ability parameters of gait may be more sensitive to pathology
compared to routine spatiotemporal measures such as velocity
(Hausdorff 2007). The lack of differences between patients and
controls is probably due to the low sample size and the relatively
mild disease severity in our cohort, since a trend toward wider
step width and longer step time variability in the post-exercise
protocol and a trend towards higher step width variability in the
pre-exercise protocols was observed.
We found good to perfect repeatability of velocity, cadence,
step length, step time, step time variability, and stepwidth in our
patients. Our reliability data are comparable to the data obtained
in children with neurological gait disorders and adult patients
with the m.3243A >G mutation, with respect to the reliability
of these spatial gait parameters (Graser et al 2016; Ramakers
et al 2017). In other studies in children with various other neu-
rological conditions, the test repeatability was generally good
(Wondra et al 2007), but tended to be variable between param-
eters (Thorpe et al 2005; Sorsdahl et al 2008) and populations
(Thorpe et al 2005; Morrison et al 2012). Since both symmetry
parameters showed low repeatability in our study, we advice
not to use these parameters for longitudinal evaluations, as rec-
ommended by Graser et al previously (Graser et al 2016).
Gait analysis is also used to quantify subtle changes in
walking patterns of children and adults with various protocols
(Galna et al 2013; Hagmann-von Arx et al 2015; Gilchrist and
Tanner 2016; Hollands et al 2016; Lim et al 2016; Manicolo
et al 2016) and was able to obtain insight in the effects of a
therapeutic intervention (Koopman et al 2012; Lord et al
2013). In our patient cohort, same-day repeatability of several
spatiotemporal parameters was good to perfect in the recovery
protocol. However, in the healthy controls, the same-day re-
peatability of the selected spatiotemporal parameters in the
recovery protocol was only acceptable for two out of six pa-
rameters and low for step time variability. This suggests that
the heterogeneity in our patient population may have falsely
increased the ICCs, as ICCs are dependent on the between-
subject variance (larger between subject variance leads to larg-
er ICCs).
For many neurological conditions, it has been shown that
the spatiotemporal parameters of gait are representative of
disease severity (Coker et al 2010; Stephenson et al 2015;
Gilchrist and Tanner 2016). The two studies in adult mito-
chondrial disease previously showed that velocity, step length,
step length variability, step time variability, and step width
variability correlate to the presence and severity of gait stabil-
ity, exercise tolerance, myopathy, and/or cerebellar ataxia
(Galna et al 2014; Ramakers et al 2017). We found no
correlations between any of the spatiotemporal parameters of
gait and the anchor we used, namely functional ambulation
(distance walked at the 3MWT). This may again be due to the
complex interplay between growth, development, maturation
of gait, and disease severity in this small sample (Di Nardo
et al 2017). Importantly, the impact of these growth and mat-
uration factors should be taken into account when intervention
studies with a longer duration using gait analysis are designed,
illustrating the importance of natural history studies.
We used the 3MWT as a Bstress test^ to enlarge the differ-
ence between patients and healthy controls. Parents report that
children have an impaired balance or trip over more frequently
after walking a long distance, and we hypothesized the
3MWT would unmask their compensatory mechanisms to
maintain normal gait. We did observe statistically significant
increased step length and step width variability between both
groups post-exercise (3.8 cm (patients) versus 3.2 cm
(controls); p = 0.02 and 3.5 cm (patients) versus 2.7 cm
(controls); p = 0.05, respectively), which were not observed
before the 3MWT (pre-exercise). When comparing the post-
and pre-3MWT gait changes in children with mitochondrial
disease to their healthy peers, healthy children tend to de-
crease their step width after the 3MWT (post-exercise proto-
col), whereas patients with mitochondrial disease do not.
Since we could only detect differences between children with
mitochondrial disease and their healthy peers in the post-
exercise protocol, we recommend using an exercise protocol
before the gait measurement to induce neuromuscular fatigue
and diminish compensatory mechanisms to maintain normal
gait.
We did not include time for practice in our study. A reli-
ability study in children with ambulatory CP allowed children
to perform two to four trials before data collection (Wondra
et al 2007). This might lead to better reliability, as shown by
the increase in the ICCs between the first (test 1 versus 2) and
the last (test 2 versus 5) comparison in our study. We advise
letting the child perform at least one well-performed walk
before starting the actual gait measurements, to induce a more
stable measurement.
Although repeatability may be lower in young or non-
typically developing children (Thorpe et al 2005; Guffey
et al 2016), we found no obvious differences in the ICC when
less-cooperative patients were excluded, which probably re-
flects that walking is an automated process which requires
little cooperation. We therefore argue that spatiotemporal pa-
rameters, especially those on the variability of gait are prom-
ising outcome measures that are universally applicable to all
ambulatory patients with mitochondrial disease.
This study has several other limitations. We assessed test-
retest reliability on the same day, within the same hour for
most subjects. Because of logistical and ethical reasons it
was not suitable to let patients visit the hospital for a second
measurement within the same week or month. Secondly, we
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included a very heterogenous sample of children who were
able to walk 30 m five times. This may enhance the general-
izability of our results to all ambulatory children with mito-
chondrial disease without severe behavioral problems, al-
though the enormous heterogeneity seen in mitochondrial dis-
eases may require a new reliability study for each separate
population. More importantly, the heterogeneity may have
positively influenced the reliability calculations, as illustrated
by the lower ICCs in the control group. Thirdly, we did not
determine responsiveness in our cohort, since no effective
intervention is available yet. In children with CP, gait param-
eters showed good responsiveness in two small short-time
intervention studies, (Kelly et al 2008; Coker et al 2010) but
since the mechanism of action of this intervention is probably
not comparable to the interventions that will be used in mito-
chondrial disease, responsiveness should still be confirmed in
future intervention studies.
In conclusion, measuring the spatiotemporal parameters of
gait using the GAITRite in ambulatory children with mito-
chondrial disease is feasible and reliable for most of the pa-
rameters measured. When using gait analysis in future studies,
we advise i) to use a (standardized) exercise test prior to the
gait analysis, ii) to let children practice the test before the
actual data collection, and iii) to not use symmetry parameters
to increase repeatability. Longitudinal natural history studies
should incorporate gait analyses in this growing and develop-
ing population to facilitate the interpretation of the data from
future intervention studies using this outcome measure.
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